The All India Institute of Medical Sciences (AIIMS), Delhi will start phase I/II of the human trials of the indigenously developed probable COVID-19 vaccine named ‘Covaxin’ on Monday. AIIMS Delhi is one of 12 sites where the human trials for Covaxin will be conducted.
Covaxin has been developed by Bharat Biotech in collaboration with Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV).
375 volunteers had registered for the human trials of Covaxin, out of which AIIMS Delhi will choose 100 volunteers for the first and second phases of the human clinical trials of the prospective COVID-19 vaccine.
In a post from his official Facebook Page, Member of Parliament from Silchar, Dr. Rajdeep Roy also informed the public about this development and expressed his prayers for both the examiners and the examinees.